Skip to content

Efficacy and safety of microwave ablation under ENB combined with VATS in the treatment of multiple high-risk pulmonary GGN.

Efficacy and safety of microwave ablation under ENB combined with VATS in the treatment of multiple high-risk pulmonary GGN.

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000040943
Enrollment
Unknown
Registered
2020-12-16
Start date
2021-01-01
Completion date
Unknown
Last updated
2021-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pulmonary nodule

Interventions

experimental group:electromagnetic navigation subbronchoscopic microwave ablation combined with thoracoscopic surgery

Sponsors

Jiangsu Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 79 Years

Inclusion criteria

Inclusion criteria: 1. Between the ages of 20 ~ 79 years old, regardless of gender; 2. Preoperative CT showed multiple pulmonary nodules, and imaging was consistent with the diagnosis of early lung cancer. 3. Multidisciplinary consultation in line with multiple primary pulmonary high-risk GGN (located in bilateral lobe)Good lung function (FEV1 >= 70%), no serious cardiopulmonary complications; 4. ECOG 0 ~ 2 for physical condition score; 5. Participate voluntarily and sign informed consent, and comply with the requirements of research visit plan and other programs.

Exclusion criteria

Exclusion criteria: 1. Patients with severe preoperative liver and renal function damage (ALT and/or AST over 3 times the normal upper limit, Cr over the normal upper limit); 2. History of serious cardiovascular diseases: 3. Patients with other malignant tumors or blood diseases; 4. Women with pregnancy, planned pregnancy and lactation (urine HCG > 2500 iu /L, diagnosed as early pregnancy); 5. Prior to tumor resection, patients underwent any form of anti-tumor therapy, including interventional chemoembolization, ablation, radiotherapy, chemotherapy, molecular targeted therapy and immunotherapy.

Design outcomes

Primary

MeasureTime frame
5-year postoperative recurrence rate and survival rate;

Secondary

MeasureTime frame
perioperative complications Length of hospital stay; Quality of life after surgery.;

Countries

China

Contacts

Public ContactLi Ming

Jiangsu Province Cancer Hospital

h136271114@163.com+86 15250961090

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026